These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. A US-based national surveillance study for the susceptibility and epidemiology of Snydman DR; McDermott LA; Thorpe CM; Goldstein EJC; Schuetz AN; Johnson S; Gerding DN; Gluck L; Bourdas D; Carroll KC; Lancaster CK; Garey KW; Wang Q; Walk ST; Duperchy E Antimicrob Agents Chemother; 2023 Oct; 67(10):e0034923. PubMed ID: 37728368 [TBL] [Abstract][Full Text] [Related]
71. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Carman RJ; Boone JH; Grover H; Wickham KN; Chen L Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175 [TBL] [Abstract][Full Text] [Related]
72. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172 [TBL] [Abstract][Full Text] [Related]
73. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile. Collins DA; Wu Y; Tateda K; Kim HJ; Vickers RJ; Riley TV J Antimicrob Chemother; 2021 Mar; 76(4):967-972. PubMed ID: 33351917 [TBL] [Abstract][Full Text] [Related]